In 2023, total pharmaceutical sales in Switzerland were valued at 7.70 billion Swiss Francs. Forecasted figures from 2024 to 2028 indicate a steady growth, with sales expected to reach 8.31 billion Swiss Francs by 2028. This represents a compound annual growth rate (CAGR) of approximately 1.56% over the five-year period from 2024 to 2028.
Year-on-year variations reveal the following percentage growth:
- 2024: 1.43%
- 2025: 1.54%
- 2026: 1.64%
- 2027: 1.49%
- 2028: 1.59%
Future trends to watch for include the impact of emerging technologies such as artificial intelligence and machine learning in drug development, the growth of personalized medicine, and the increasing adoption of digital health solutions. Furthermore, regulatory changes and pricing dynamics could influence market dynamics significantly.
